Free Trial

October's 4 Best Penny Stocks: High-Risk, High-Reward Picks

Penny stocks October Fall

Key Points

  • Penny stocks offer a high-risk, high-reward prospect for investors willing to tolerate their illiquidity and volatility.
  • Still, these companies make it possible for investors to reap significant rewards for a minimal investment.
  • When considering penny stocks, it's important to be aware of scams and companies that have suffered significant share declines due to adverse fundamentals.
  • 5 stocks we like better than Gevo.

Most investors' definition of a penny stock has broadened to include not just companies trading at less than $1 per share, but also those with slightly higher stock prices up to about $5 per share. Regardless of your exact threshold, these firms remain a high-risk, high-reward proposition. Companies in the penny stock category are often newly-established and untested, or are heading toward bankruptcy, or are otherwise less stable than higher-value stocks. Many penny stocks lack liquidity and are the target of scammers looking to execute a pump-and-dump scheme or something similar.

On the other hand, though, penny stocks do offer investors the possibility of a significant reward at a low cost. Being able to load up on affordable shares of an up-and-coming company before it breaks out is an attractive draw of the penny stock market for many investors. When selecting penny stocks, then, it's crucial to consider companies with solid fundamentals and a compelling case for growth.

ALUR: Solid Weight Loss Management Program

Allurion Technologies Today

Allurion Technologies Inc. stock logo
ALURALUR 90-day performance
Allurion Technologies
$0.71
+0.02 (+2.52%)
(As of 11:11 AM ET)
52-Week Range
$0.55
$5.15
Price Target
$2.88

Allurion Technologies Inc. NYSE: ALUR offers a program designed to help patients lose weight via a procedure less intragastric balloon. The weight loss management market is expected to more than double from 2023 to 2032 to a size of more than $328 billion. Allurion recently set itself apart from competitors in this field with a positive systematic review and meta-analysis of its program in October, which found that the treatment is both safe and effective.

Allurion reported roughly 25% quarter-over-quarter revenue growth in the latest quarter despite headwinds, including regulatory barriers in France. Analysts overwhelmingly view the company as a Buy, with an average price target of $2.88, about four times the current price level.

LUCD: Strong Trajectory in an Untapped Market

Lucid Diagnostics Today

Lucid Diagnostics Inc. stock logo
LUCDLUCD 90-day performance
Lucid Diagnostics
$0.82
-0.01 (-1.70%)
(As of 11:08 AM ET)
52-Week Range
$0.63
$1.58
Price Target
$3.94

Lucid Diagnostics Inc. NASDAQ: LUCD is a medical diagnostics company providing a tool to check for precancer among patients with gastroesophageal reflux disease (GERD). GERD affects some 20% of people across the U.S.

Lucid's flagship EsoGuard test product is growing rapidly in popularity; the company reported a 31% quarter-over-quarter increase in tests performed for the second quarter of the year. Lucid's revenue trajectory has been strong as well, as revenue roughly quintupled year-over-year for the most recent period. Lucid seems poised to capture a significant portion of a U.S. market estimated to be worth $25 billion.

KULR: Key Role in Green Energy and Data Center Spaces

KULR Technology Group Today

KULR Technology Group, Inc. stock logo
KULRKULR 90-day performance
KULR Technology Group
$0.29
0.00 (-0.86%)
(As of 11:08 AM ET)
52-Week Range
$0.10
$0.90
Price Target
$1.00

KULR Technology Group Inc. NYSEAMERICAN: KULR develops thermal shields, screening and test systems, and other equipment for batteries. The company is emerging as a leader in the transition toward sustainable energy management. It recently announced a landmark $2.4-million extension of its prior contract with the U.S. Army and a similarly-sized licensing agreement for its vibration reduction technology KULR Xero Vibe.

The latter of these agreements is particularly notable, as the licensee will use KULR's technology to aid in cooling data centers. Given the continuing and dramatic growth of both the green energy and data center markets, KULR is establishing itself as a go-to firm in multiple important industries.

GEVO: Renewable Natural Gas Leader

Gevo Today

Gevo, Inc. stock logo
GEVOGEVO 90-day performance
Gevo
$1.66
+0.03 (+1.66%)
(As of 11:16 AM ET)
52-Week Range
$0.48
$1.84
Price Target
$5.68

Renewable fuels maker Gevo Inc. NASDAQ: GEVO has an average trading volume of 5.2 million shares, making it among the more liquid penny stocks available at this time. It's no surprise, too, given that the company has reaped the benefits of the Inflation Reduction Act, which has funneled money toward the renewable energy industry. Gevo shares are up more than 48% in the last year.

While Gevo's primary operations are in aviation fuel, its renewable natural gas (RNG) business is also growing rapidly. In the most recent quarter, the company produced a record-setting annualized 400,000 British thermal units of RNG. Further, its subsidiary Verity is a leader in AI-based supply chain management, an essential component of the renewable fuel industry. Analysts have assigned Gevo an average price target of $5.68, more than triple its current value.

Penny Stock Volatility

Timing the market is always a daunting task, but this is especially so for penny stocks, which are known to be highly volatile. Given the low prices of penny stocks, even a small adjustment up or down represents a significant stock movement, which can mislead investors.

Should you invest $1,000 in Gevo right now?

Before you consider Gevo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gevo wasn't on the list.

While Gevo currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Nathan Reiff
About The Author

Nathan Reiff

Contributing Author

Fundamental analysis, ETFs, Consumer Staples

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Allurion Technologies (ALUR)
2.5242 of 5 stars
$0.72+3.2%N/A-0.19Buy$2.88
Lucid Diagnostics (LUCD)
2.6246 of 5 stars
$0.82-1.7%N/A-0.64Buy$3.94
KULR Technology Group (KULR)
3.1876 of 5 stars
$0.29-0.7%N/A-1.61Buy$1.00
Gevo (GEVO)
2.4455 of 5 stars
$1.63-0.3%N/A-5.60Moderate Buy$5.68
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

ETF Battle: SPY or VOO – Which One Should You Buy?

ETF Battle: SPY or VOO – Which One Should You Buy?

Comparing S&P 500 ETFs: SPY and VOO. Thomas and Chris break down the key differences and similarities between these two giants in the ETF world.

Related Videos

Set It and Forget It: Top ETFs for Stress-Free Investing
Market Fear Spikes as Recession Looms: What It Means For Your Stocks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines